Cited 0 times in Scipus Cited Count

A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma

Authors
Kim, MK | Kim, K | Min, CK | Kwak, JY | Bae, SB | Yoon, SS | Lee, JJ | Kim, KH | Nam, SH | Mun, YC | Kim, HJ | Bae, SH | Shin, HJ | Lee, JH | Park, JS  | Jeong, SH  | Lee, MH | Kim, YS | Lee, HS | Park, KW | Lee, WS | Lee, SM | Lee, JO | Hyun, MS | Jo, DY | Lim, SN | Lee, JH | Cho, DY | Do, YR | Kim, JA | Park, SK | Kim, JS | Kim, SJ | Kim, H | Yi, HG | Moon, JH | Choi, CW | Kim, SH | Joo, YD | Kim, HG | Kim, BS | Park, MR | Song, MK | Kim, SY
Citation
Oncotarget, 8(23). : 37605-37618, 2017
Journal Title
Oncotarget
ISSN
1949-2553
Abstract
Bortezomib-melphalan-prednisone (VMP) showed superior efficacy versus MP as first-line treatment for transplantation-ineligible multiple myeloma (MM). This study investigated the efficacy of VMP for Korean patients with MM.Overall, 177 MM patients received 9 cycles of VMP in this prospective, multicenter, observational study. The primary endpoint was 2-year progression-free survival (PFS).Thirty-nine (22%) patients were aged >/= 75 years and 83 (47.4%) patients had International Staging System stage III. A median of 5 cycles were delivered. Overall response rate (ORR) was 72.9%, and complete response (CR) rate was 20.3%. With a median follow-up of 11.9 months, median PFS was 17 months. The 2-year PFS and overall survival (OS) rates were 29.2% and 80.0%, respectively. Median OS was not reached. PFS was significantly different depending on performance status (Eastern Cooperative Oncology Group < 2 vs. >/= 2: p = 0.0002), beta2-microglobulin level (< 5.5 vs. >/= 5.5 mg/L: p = 0.0481), and cumulative dose of bortezomib (< 35.1 vs. >/= 35.1 mg/m2: p < 0001). The common adverse events (AEs) were in line with the well-known toxicity profiles associated with VMP.In conclusion, VMP is a feasible and effective front-line treatment for transplant-ineligible older patients with MM in Korea. Continuing therapy with prompt adjustment of treatment according to AEs may be important to improve outcomes of elderly patients.
MeSH

DOI
10.18632/oncotarget.16790
PMID
28402945
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Ajou Authors
박, 준성  |  정, 성현
Full Text Link
Files in This Item:
28402945.pdfDownload
Export

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse